SCHEMBL75349

SCHEMBL75349

COC(=O)C(N)(c1ccccc1)C1CC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNN4 O15554 1/20 0.53
CYP1A2 P05177 2/20 0.45
MEN1 O00255 1/20 0.45
CYP2C19 P33261 1/20 0.45
KMT2A Q03164 1/20 0.45
KEAP1 Q14145 1/20 0.44
NFE2L2 Q16236 1/20 0.44
SRC P12931 1/20 0.41
CHRM3 P20309 8/20 0.41
ALDH1A1 P00352 2/20 0.41
CHRM2 P08172 2/20 0.40
KIF11 P52732 1/20 0.40
CHRM4 P08173 1/20 0.39
CHRM5 P08912 1/20 0.39
CHRM1 P11229 1/20 0.39
HRH1 P35367 1/20 0.39
HTR2B P41595 1/20 0.39
KCNH2 Q12809 1/20 0.39
POLB P06746 1/20 0.39
GLA P06280 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL75620 0.82 KCNN4 (0.45) KCNN4CYP1A2CHRM3CHRM2
SCHEMBL29002624 0.81 KMT2A (0.49) KCNN4CYP1A2MEN1CYP2C19KMT2A
SCHEMBL28645834 0.79 KMT2A (0.50) KCNN4CYP1A2MEN1CYP2C19KMT2A
SCHEMBL10842570 0.78 KEAP1 (0.62) KCNN4CYP1A2CYP2C19KEAP1NFE2L2
SCHEMBL1411424 0.77 KEAP1 (0.61) KCNN4CYP1A2MEN1CYP2C19KMT2A
SCHEMBL2451043 0.77 CYP1A2 (0.57) KCNN4CYP1A2MEN1CYP2C19KMT2A
SCHEMBL2451041 0.77 CYP1A2 (0.57) KCNN4CYP1A2MEN1CYP2C19KMT2A
SCHEMBL1410564 0.77 KEAP1 (0.61) KCNN4CYP1A2MEN1CYP2C19KMT2A
SCHEMBL75592 0.77 KDM4E (0.41) KCNN4CYP1A2MEN1CYP2C19KMT2A
SCHEMBL9516976 0.75 KEAP1 (0.53) CYP1A2MEN1CYP2C19KMT2AKEAP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8129423-B2 1-Adamantan-2-yl-3-benzyl-1,3-dihydro-imidazol-2-one; 11beta-hydroxysteroid dehydrogenases (11beta-HSD) inhibitor; antidiabetic, hypotensive, hypoglycemic agent; resist hyperglycemia provoked by obesity or stress; HOFFMAN-LA ROCHE INC. (US) 2012-03-06 US disclosed
EP-2308851-A1 Imidazolone and imidazolidinone derivatives as 11B-HSD1 inhibitors for the treatment of diabetes F. Hoffmann-La Roche AG (CH) 2011-04-13 EP disclosed
CN-101553474-A Imidazolidinone and imidazolidinone derivatives as 11 b-HSD 1 inhibitors for diabetes HOFFMANN LA ROCHE (CH) 2009-10-07 CN disclosed
EP-2104665-A2 IMIDAZOLONE AND IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS FOR DIABETES F. Hoffmann-Roche AG (CH) 2009-09-30 EP disclosed
US-20080103183-A1 NEW IMIDAZOLONE AND IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS HOFFMANN-LA ROCHE INC. 2008-05-01 US disclosed
WO-2008046758-A2 IMIDAZOLONE AND IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS FOR DIABETES F. HOFFMANN-LA ROCHE AG (CH) 2008-04-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080103183-A1 NEW IMIDAZOLONE AND IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS HSD11B1, HSD17B1, HSD17B11 KCNN4 4571/4885CYP1A2 67/4885MEN1 434/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.